Guardant360 test results may provide prognostic information beyond the detection of actionable biomarkers for ALK-rearranged NSCLC patients
- Saturday, May 30, 2020, 7:03
- Finance
- Add a comment
SINGAPORE, May 30, 2020 /PRNewswire/ — According to the data presented at the American Society of Clinical Oncology (ASCO) Annual Meeting on 29 May 2020, researchers at Samsung Medical Center in Seoul, Korea, have found useful prognostic information beyond actionable biomarkers when the…
About the Author
adminasapcorp has written 38945 stories on this site.